Literature DB >> 14636351

The multicenter study of epilepsy surgery: recruitment and selection for surgery.

Anne T Berg1, Barbara G Vickrey, John T Langfitt, Michael R Sperling, Thaddeus S Walczak, Shlomo Shinnar, Carl W Bazil, Steven V Pacia, Susan S Spencer.   

Abstract

PURPOSE: Multiple studies have examined predictors of seizure outcomes after epilepsy surgery. Most are single-center series with limited sample size. Little information is available about the selection process for surgery and, in particular, the proportion of patients who ultimately have surgery and the characteristics that identify those who do versus those who do not. Such information is necessary for providing the epidemiologic and clinical context in which epilepsy surgery is currently performed in the United States and in other developed countries.
METHODS: An observational cohort of 565 surgical candidates was prospectively recruited from June 1996 through January 2001 at six Northeastern and one Midwestern surgical centers. Standardized eligibility criteria and protocol for presurgical evaluations were used at all seven sites.
RESULTS: Three hundred ninety-six (70%) study subjects had resective surgery. Clinical factors such as a well-localized magnetic resonance imaging (MRI) abnormality and consistently localized EEG findings were most strongly associated with having surgery. Of those who underwent intracranial monitoring (189, 34%), 85% went on to have surgery. Race/ethnicity and marital status were marginally associated with having surgery. Age, education, and employment status were not. Demographic factors had little influence over the surgical decision. More than half of the patients had intractable epilepsy for >/=10 years and five or more drugs had failed by the time they initiated their surgical evaluation. During the recruitment period, eight new antiepileptic drugs were approved by the Food and Drug Administration for use in the United States and came into increasing use in this study's surgical candidates. Despite the increased availability of new therapeutic options, the proportion that had surgery each year did not fluctuate significantly from year to year. This suggests that, in this group of patients, the new drugs did not provide a substantial therapeutic benefit.
CONCLUSIONS: Up to 30% of patients who undergo presurgical evaluations for resective epilepsy surgery ultimately do not have this form of surgery. This is a group whose needs are not currently met by available therapies and procedures. Lack of clear localizing evidence appears to be the main reason for not having surgery. To the extent that these data can address the question, they suggest that repeated attempts to control intractable epilepsy with new drugs will not result in sustained seizure control, and eligible patients will proceed to surgery eventually. This is consistent with recent arguments to consider surgery earlier rather than later in the course of epilepsy. Postsurgical follow-up of this group will permit a detailed analysis of presurgical factors that predict the best and worst seizure outcomes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636351     DOI: 10.1046/j.1528-1157.2003.24203.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  46 in total

1.  Operating in the dark ... to see is to cure.

Authors:  Gregory A Worrell
Journal:  Epilepsy Curr       Date:  2010-07       Impact factor: 7.500

2.  Postsurgical treatment of epilepsy.

Authors:  Anne T Berg
Journal:  Epilepsy Curr       Date:  2004 Jul-Aug       Impact factor: 7.500

3.  First findings from the multicenter study of epilepsy surgery.

Authors:  William J Marks
Journal:  Epilepsy Curr       Date:  2004 Jul-Aug       Impact factor: 7.500

4.  Localizing seizure-onset zones in presurgical evaluation of drug-resistant epilepsy by electroencephalography/fMRI: effectiveness of alternative thresholding strategies.

Authors:  M Hauf; K Jann; K Schindler; O Scheidegger; K Meyer; C Rummel; L Mariani; T Koenig; R Wiest
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

5.  Validity and responsiveness of generic preference-based HRQOL instruments in chronic epilepsy.

Authors:  J T Langfitt; B G Vickrey; M P McDermott; S Messing; A T Berg; S S Spencer; M R Sperling; C W Bazil; S Shinnar
Journal:  Qual Life Res       Date:  2006-06       Impact factor: 4.147

Review 6.  Evidence from clinical trials: can we do better?

Authors:  Andrew D Siderowf
Journal:  NeuroRx       Date:  2004-07

7.  Determination of epileptic focus side in mesial temporal lobe epilepsy using long-term noninvasive fNIRS/EEG monitoring for presurgical evaluation.

Authors:  Edmi Edison Rizki; Minako Uga; Ippeita Dan; Haruka Dan; Daisuke Tsuzuki; Hidenori Yokota; Keiji Oguro; Eiju Watanabe
Journal:  Neurophotonics       Date:  2015-05-20       Impact factor: 3.593

8.  Searching for the lesion in "MRI-normal" neocortical epilepsy--plumb the depths!

Authors:  John W Miller
Journal:  Epilepsy Curr       Date:  2009 Nov-Dec       Impact factor: 7.500

9.  Disparities in epilepsy surgery in the United States of America.

Authors:  Iván Sánchez Fernández; Christopher Stephen; Tobias Loddenkemper
Journal:  J Neurol       Date:  2017-07-12       Impact factor: 4.849

10.  Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists omega-conotoxin GVIA and omega-conotoxin MVIIA.

Authors:  Maciej Gasior; Natalie A White; Michael A Rogawski
Journal:  J Pharmacol Exp Ther       Date:  2007-08-23       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.